Figure 2From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsKaplan-Meier plot of progression-free survival (PFS) for modified intent-to-treat (mITT) population (solid line). Dashed lines represent 95% confidence intervals and circles indicate censored patients.Back to article page